Artemisininderived

Artemisinin-derived drugs, often referred to as artemisinins, are a class of medications used to treat malaria. They are derived from artemisinin, a compound found in the leaves of the Artemisia annua plant, also known as sweet wormwood. Artemisinin was first isolated in the 1970s by Chinese scientist Tu Youyou, who was awarded the Nobel Prize in Physiology or Medicine in 2015 for her discovery.

The primary mechanism of action for artemisinins involves the release of reactive oxygen species within the malaria parasite, Plasmodium falciparum. This process damages the parasite's membranes and proteins, leading to its death. Artemisinins are rapidly acting and highly effective against the blood stages of the parasite.

Artemisinin-derived drugs are typically used in combination therapy, known as artemisinin-based combination therapies (ACTs). This approach combines an artemisinin derivative with a longer-acting partner drug. ACTs are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria by the World Health Organization. The combination therapy helps to reduce the risk of developing drug resistance, as the partner drug clears any residual parasites that might survive the artemisinin's rapid action.

Common artemisinin derivatives include artemether, artesunate, and dihydroartemisinin. These drugs are generally well-tolerated, with side effects being infrequent and mild. Resistance to artemisinins has emerged in some regions of Southeast Asia, prompting ongoing surveillance and research into new antimalarial drugs and strategies.